Trial Profile
Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Aliskiren/amlodipine (Primary) ; Aliskiren/amlodipine/hydrochlorothiazide (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms ACADEMY
- Sponsors Novartis
- 22 Aug 2011 Actual end date (October 2010) added as reported by ClinicalTrials.gov.
- 22 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2010 Actual initiation date (Jan 2010) added as reported by ClinicalTrials.gov.